Inj thiotepa nos 1 mg
Products billed under this code include Tepadina, Thiotepa.
Payment limit per 1 MG, by effective quarter, 3Q25 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under J9342
From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Tepadina | Amneal Pharmaceuticals, LLC | 70121-1630-01 | 15 | $88.065 |
| Tepadina | Amneal Pharmaceuticals, LLC | 70121-1631-01 | 100 | $587.10 |
| Tepadina | Amneal Pharmaceuticals, LLC | 70121-2749-01 | 200 | $1,174.20 |
| Thiotepa | Hikma Pharmaceuticals USA Inc. | 00143-9292-01 | 100 | $587.10 |
| Thiotepa | Hikma Pharmaceuticals USA Inc. | 00143-9309-01 | 15 | $88.065 |
| Thiotepa | Hikma Pharmaceuticals USA Inc. | 00143-9565-01 | 15 | $88.065 |
| Thiotepa | Sagent Pharmaceuticals | 25021-0246-02 | 15 | $88.065 |
| Thiotepa | Dr. Reddy's Laboratories Inc. | 43598-0171-11 | 100 | $587.10 |
| Thiotepa | Dr. Reddy's Laboratories Inc. | 43598-0650-11 | 15 | $88.065 |
| Thiotepa | FreseniUS Kabi USA, LLC | 65219-0029-20 | 100 | $587.10 |
Show all 14 products
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Thiotepa | Meitheal Pharmaceuticals Inc. | 71288-0156-05 | 15 | $88.065 |
| Thiotepa | Meitheal Pharmaceuticals Inc. | 71288-0157-10 | 100 | $587.10 |
| Thiotepa | Novadoz Pharmaceuticals LLC | 72205-0045-01 | 15 | $88.065 |
| Thiotepa | Novadoz Pharmaceuticals LLC | 72205-0046-01 | 100 | $587.10 |
Every quarter
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $5.871 | +$0.94 | 1 MG | Inj thiotepa nos 1 mg | v1, posted September 17, 2026 |
| 3Q26 | $4.931 | −$0.807 | 1 MG | Inj thiotepa nos 1 mg | v1, posted September 15, 2026 |
| 2Q26 | $5.738 | −$3.125 | 1 MG | Inj thiotepa nos 1 mg | v1, posted September 15, 2026 |
| 1Q26 | $8.863 | −$1.674 | 1 MG | Inj thiotepa nos 1 mg | v1, posted September 15, 2026 |
| 4Q25 | $10.537 | −$1.699 | 1 MG | Inj thiotepa nos 1 mg | v1, posted September 8, 2026 |
| 3Q25 | $12.236 | – | 1 MG | Inj thiotepa nos 1 mg | v1, posted March 10, 2026 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.
CMS source files
- 4Q26: 2026-09-17_october-2026-medicare-part-b-payment-limit-files-final.zipposted September 17, 2026
- 4Q26: 2026-09-17_october-2026-ndc-hcpcs-crosswalk-final.zipposted September 17, 2026
- 3Q26: 2026-09-15_july-2026-medicare-part-b-payment-limit-files.zipposted September 15, 2026
- 2Q26: 2026-09-15_april-2026-medicare-part-b-payment-limit-files-final-file.zipposted September 15, 2026
- 1Q26: 2026-09-15_january-2026-medicare-part-b-payment-limit-files.zipposted September 15, 2026
- 4Q25: 2026-09-08_october-2025-asp-pricing-final-file.zipposted September 8, 2026
- 3Q25: 2026-03-10_july-2025-asp-pricing-file.zipposted March 10, 2026